Literature DB >> 27979923

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.

Gilles Salles1, Stephen J Schuster2, Sven de Vos3, Nina D Wagner-Johnston4, Andreas Viardot5, Kristie A Blum6, Christopher R Flowers7, Wojciech J Jurczak8, Ian W Flinn9, Brad S Kahl10, Peter Martin11, Yeonhee Kim12, Sanatan Shreay12, Matthias Will13, Bess Sorensen13, Madlaina Breuleux13, Pier Luigi Zinzani14, Ajay K Gopal15.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27979923      PMCID: PMC5395130          DOI: 10.3324/haematol.2016.151738

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.

Authors:  Daryl Tan; Sandra J Horning; Richard T Hoppe; Ronald Levy; Saul A Rosenberg; Bronislava M Sigal; Roger A Warnke; Yasodha Natkunam; Summer S Han; Alan Yuen; Sylvia K Plevritis; Ranjana H Advani
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

3.  Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

Authors:  Myron S Czuczman; Luis Fayad; Vincent Delwail; Guillaume Cartron; Eric Jacobsen; Kazimierz Kuliczkowski; Brian K Link; Lauren Pinter-Brown; John Radford; Andrzej Hellmann; Eve Gallop-Evans; Christine G DiRienzo; Nancy Goldstein; Ira Gupta; Roxanne C Jewell; Thomas S Lin; Steen Lisby; Martin Schultz; Charlotte A Russell; Anton Hagenbeek
Journal:  Blood       Date:  2012-03-02       Impact factor: 22.113

4.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Authors:  Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

5.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Authors:  Carla Casulo; Michelle Byrtek; Keith L Dawson; Xiaolei Zhou; Charles M Farber; Christopher R Flowers; John D Hainsworth; Matthew J Maurer; James R Cerhan; Brian K Link; Andrew D Zelenetz; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544

6.  Fludarabine in alkylator-resistant follicular non-Hodgkin's lymphoma.

Authors:  A Tinmouth; B Zanke; K R Imrie
Journal:  Leuk Lymphoma       Date:  2001-03

7.  Improved survival of follicular lymphoma patients in the United States.

Authors:  Wade T Swenson; James E Wooldridge; Charles F Lynch; Valerie L Forman-Hoffman; Elizabeth Chrischilles; Brian K Link
Journal:  J Clin Oncol       Date:  2005-06-27       Impact factor: 44.544

Review 8.  Management of indolent lymphoma: where are we now and where are we going.

Authors:  Matthew A Lunning; Julie M Vose
Journal:  Blood Rev       Date:  2012-10-09       Impact factor: 8.250

9.  Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.

Authors:  Brad S Kahl; Nancy L Bartlett; John P Leonard; Ling Chen; Kristen Ganjoo; Michael E Williams; Myron S Czuczman; K Sue Robinson; Robin Joyce; Richard H van der Jagt; Bruce D Cheson
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

10.  Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.

Authors:  Thomas E Witzig; Peter H Wiernik; Timothy Moore; Craig Reeder; Craig Cole; Glen Justice; Henry Kaplan; Michael Voralia; Dennis Pietronigro; Kenichi Takeshita; Annette Ervin-Haynes; Jerome B Zeldis; Julie M Vose
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

View more
  29 in total

1.  Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma.

Authors:  Yucai Wang; Matthew J Maurer; Melissa C Larson; Cristine Allmer; Andrew L Feldman; N Nora Bennani; Carrie A Thompson; Luis F Porrata; Thomas M Habermann; Thomas E Witzig; Stephen M Ansell; Susan L Slager; Grzegorz S Nowakowski; James R Cerhan
Journal:  Br J Haematol       Date:  2019-05-28       Impact factor: 6.998

Review 2.  From genetics to the clinic: a translational perspective on follicular lymphoma.

Authors:  Sarah Huet; Pierre Sujobert; Gilles Salles
Journal:  Nat Rev Cancer       Date:  2018-02-09       Impact factor: 60.716

3.  Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Authors:  Stephen J Schuster; Jakub Svoboda; Elise A Chong; Sunita D Nasta; Anthony R Mato; Özlem Anak; Jennifer L Brogdon; Iulian Pruteanu-Malinici; Vijay Bhoj; Daniel Landsburg; Mariusz Wasik; Bruce L Levine; Simon F Lacey; Jan J Melenhorst; David L Porter; Carl H June
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

Review 4.  Indolent lymphomas: pushing the pace with novel agents.

Authors:  Caron A Jacobson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 5.  How do I sequence therapy for follicular lymphoma?

Authors:  Gilles Salles
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

6.  Cardiovascular complications associated with novel agents in the chronic lymphocytic leukemia armamentarium: A pharmacovigilance analysis.

Authors:  Udhayvir Singh Grewal; Sahith Reddy Thotamgari; Aakash Rajendra Sheth; Shiva Jashwanth Gaddam; Javaria Ahmad; Kavitha Beedupalli; Paari Dominic
Journal:  Int J Cardiol       Date:  2021-10-12       Impact factor: 4.164

Review 7.  Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.

Authors:  Allison Rosenthal
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

8.  Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model.

Authors:  Çağlar Çağlayan; Hiromi Terawaki; Turgay Ayer; Jordan S Goldstein; Ashish Rai; Qiushi Chen; Christopher Flowers
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-01-03

9.  Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.

Authors:  Hui Guo; Dongfeng Zeng; Hui Zhang; Taylor Bell; Jun Yao; Yang Liu; Shengjian Huang; Carrie J Li; Elizabeth Lorence; Shouhao Zhou; Tiejun Gong; Changying Jiang; Makhdum Ahmed; Yixin Yao; Krystle J Nomie; Liang Zhang; Michael Wang
Journal:  Oncogene       Date:  2018-10-25       Impact factor: 9.867

Review 10.  PI3K inhibitors are finally coming of age.

Authors:  Bart Vanhaesebroeck; Matthew W D Perry; Jennifer R Brown; Fabrice André; Klaus Okkenhaug
Journal:  Nat Rev Drug Discov       Date:  2021-06-14       Impact factor: 112.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.